Guido Koopmans
Gründer bei Algiax Pharmaceuticals GmbH
Profil
Guido Koopmans is the founder of Algiax Pharmaceuticals GmbH, where he holds the title of Chief Scientific Officer since 2019.
He also founded Algiax Pharmaceuticals GmbH in 2011.
Currently, Dr. Koopmans is the Head-Clinical Research at SCT-Spinal Cord Therapeutics GmbH.
Dr. Koopmans obtained a doctorate degree from Maastricht University.
Aktive Positionen von Guido Koopmans
Unternehmen | Position | Beginn |
---|---|---|
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | Technik-/Wissenschafts-/F&E-Leiter | - |
Algiax Pharmaceuticals GmbH
Algiax Pharmaceuticals GmbH BiotechnologyHealth Technology Algiax Pharmaceuticals GmbH operates as an independent biotechnology company. It discovers and develops products in the field of nervous system disease or dysfunction with a focus on neuropathic pain. The company was founded by Stefan Fischer, Jurgen Schumacher, Guido Koopmans and Birgit Hasse in April 2011 and is headquartered in Erkrath, Germany. | Gründer | 01.04.2011 |
Ausbildung von Guido Koopmans
Maastricht University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
SCT-Spinal Cord Therapeutics GmbH
SCT-Spinal Cord Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services SCT-Spinal Cord Therapeutics GmbH, a biopharmaceutical company based in Düsseldorf, Germany, is focused on the treatment of traumatic injury to the central nervous system. SCT`s proprietary key technology, the Regeneration Promoting Treatment, is an unique and promising treatment approach aimed at the supression of scar formation. The inhibition of scar formation allows the severed nerves to sprout and/or regenerate which in turn enables the recovery of sensory and motor function. As a first application of the Regeneration Promoting Treatment SCT is focusing on the development of Cordaneurin, a drug for the treatment of acute spinal cord injuries. In pre-clinical studies Cordaneurin has demonstrated its efficacy in the recovery of motor function after spinal cord contusion. | Commercial Services |
Algiax Pharmaceuticals GmbH
Algiax Pharmaceuticals GmbH BiotechnologyHealth Technology Algiax Pharmaceuticals GmbH operates as an independent biotechnology company. It discovers and develops products in the field of nervous system disease or dysfunction with a focus on neuropathic pain. The company was founded by Stefan Fischer, Jurgen Schumacher, Guido Koopmans and Birgit Hasse in April 2011 and is headquartered in Erkrath, Germany. | Health Technology |